JPRN-UMIN000004788已完成未知
Immunogenicity and cross-immunity after booster immunization with adjuvanted whole virion A (H5N1) vaccine of Qinghai strain Part2 Immunization effect on adults who might be exposed to H5N1 viral components - A non-blind phase 4 clinical trial with adjuvanted whole virion A (H5N1) vaccine of Qinghai strain Part2 Immunization effect on adults who might be exposed to H5N1 viral components (H5N1_QB2)
Clinical Research Center, National Hospital Organization0 个研究点目标入组 300 人开始时间: 2010年12月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Individuals with the history of Swine Influenza A (H5N1) virus infection. (obtained by subjects) 2) Individuals, who had history of anaphylaxis to foods or medicines previously. 3) Individuals with severe diseases in cardiovascular, blood, respiratory, liver, kidney, digestive or neurological systems in their clinical recording. 4) Individuals with a history of acute disseminated encephalomyelitis and Guillain-Barre syndrome in the past. 5) Individuals participated in a clinical trial with influenza vaccine within four months (counted from the date of vaccination). 6) Individuals vaccinated with live vaccine within 27 days, or received a dose of inactivated vaccine within six days (counting from the date of vaccination). 7) Individuals received with gamma globulin or blood transfusion within three months, or received the formulation of high dose of gamma globulin therapy (200 mg / kg or more) within six months (counting from the date of vaccination). 8)Individuals who are deemed to be inappropriate by the investigator
研究者
相似试验
已完成
不适用
Immunogenicity and cross-immunity after booster immunization with adjuvanted whole virion A (H5N1) vaccine of Qinghai straiPrevention of influenzaJPRN-UMIN000004169Clinical Research Center, National Hospital Organization320
进行中（未招募）
1 期
Study to Evaluate the Immune Response after a Booster Dose of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Alone or Concomitantly with a Licensed Meningococcal Serogroup B Vaccine,in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4)Healthy volunteers (active immunization against invasive meningogoccal disease (IMD) caused by Meningococcal serogroups A, C, Y and W)MedDRA version: 20.0Level: PTClassification code 10027274Term: Meningococcal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2019-004461-41-Outside-EU/EEASanofi Pasteur Inc570
进行中（未招募）
不适用
Study of a Booster Injection of Pentaxim™ Vaccine Administered With Sanofi Pasteur's Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in MexicoPrevention of symptomatic dengue diseaseEUCTR2014-001736-11-Outside-EU/EEASanofi Pasteur SA732
进行中（未招募）
1 期
Immunological responses after concomitant vaccination with the yellow fever-vaccine and the TBE-vaccine, or JE-vaccinePrevention of TBE or Japanece encephalitis by co-vaccination with the yellow fever vaccineEUCTR2017-002137-32-SEHans-Gustaf Ljunggren140
尚未招募
4 期
Safety and Immunogenicity of a booster dose of inactivated Vero-cell-derived Japanese Encephalitis vaccine (JEVAC) in children whom primed with live attenuated JE vaccine.Healthy childrenJapanese encephalitisJapanese encephalitis vaccineImmunogenicityBoosterInactivated JE vaccineTCTR20190507007iaoning Cheng Biotechnology, Shenyang150